List of Excipients in Branded Drug ABACAVIR, LAMIVUDINE AND ZIDOVUDINE

« Back to Dashboard

Generic Drugs Containing ABACAVIR, LAMIVUDINE AND ZIDOVUDINE

Company	Ingredient	NDC	Excipient
Lupin Pharmaceuticals Inc	abacavir , lamivudine and zidovudine	68180-286	CELLULOSE, MICROCRYSTALLINE
Lupin Pharmaceuticals Inc	abacavir , lamivudine and zidovudine	68180-286	CROSPOVIDONE
Lupin Pharmaceuticals Inc	abacavir , lamivudine and zidovudine	68180-286	FD&C BLUE NO. 2
Lupin Pharmaceuticals Inc	abacavir , lamivudine and zidovudine	68180-286	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in ABACAVIR, LAMIVUDINE AND ZIDOVUDINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	FD&C BLUE NO. 2
1	FERRIC OXIDE YELLOW

Last updated: August 22, 2026

Abacavir/lamivudine/zidovudine is a mature, off-patent fixed-dose antiretroviral combination with limited branded commercial value and a low technical barrier to generic manufacture. Its principal excipient opportunities are cost reduction, tablet robustness, moisture control, coating performance, and supply-chain substitution rather than differentiated drug delivery. The product’s market is constrained by once-daily integrase-inhibitor regimens, zidovudine toxicity, abacavir hypersensitivity risk, and availability of lower-pill-burden combinations.

Abacavir, Lamivudine and Zidovudine Excipient Strategy and Commercial Opportunities

What is the commercial status of abacavir, lamivudine and zidovudine?

The combination was marketed by GlaxoSmithKline as Trizivir. Each tablet contains 300 mg abacavir, 150 mg lamivudine, and 300 mg zidovudine. The U.S. Food and Drug Administration approved Trizivir in November 2000 for treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg who are appropriate candidates for the individual components.[1]

The product is now a legacy nucleoside reverse transcriptase inhibitor regimen. Current HIV treatment guidelines generally favor integrase strand transfer inhibitor-based combinations, including dolutegravir- and bictegravir-containing products, because of dosing convenience, resistance profiles, and improved tolerability.[2]

Commercial opportunities remain in:

• Low-cost generic supply for price-sensitive markets.
• Government and donor procurement.
• Markets where zidovudine remains used in treatment or prevention protocols.
• Hospital and public-sector tenders requiring a single tablet.
• Regional products using locally sourced excipients.
• Reformulated tablets with improved mechanical strength, lower friability, or reduced manufacturing cost.

The main limitation is demand erosion. The product is not a premium reformulation candidate unless a manufacturer can establish a regulatory, supply, or adherence advantage.

What excipients are used in the fixed-dose tablet?

The branded Trizivir tablet uses conventional immediate-release oral-tablet excipients. FDA labeling identifies a tablet core containing microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The film coat contains hypromellose, titanium dioxide, polyethylene glycol, and yellow iron oxide.[1]

Formulation function	Typical excipient in the branded product	Strategic role
Diluent and compressibility	Microcrystalline cellulose	Supports direct compression and tablet strength
Disintegrant	Sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film former	Hypromellose	Protects the core and improves swallowability
Plasticizer or coating aid	Polyethylene glycol	Improves coating flexibility
Opacifier	Titanium dioxide	Provides opacity and color consistency
Colorant	Yellow iron oxide	Supports product identification

The formulation has a high total active load of 750 mg before salt-equivalent adjustments and excipients. That load makes powder flow, blend uniformity, compression force, and tablet dimensions important development constraints.

How should manufacturers optimize the excipient system?

A generic manufacturer should preserve the product’s immediate-release performance while evaluating excipient substitutions through a quality-by-design program. The most practical strategy is a conventional, direct-compression or dry-granulation platform.

Tablet strength and friability

The active ingredients create a high-dose tablet with limited room for excess excipient. Microcrystalline cellulose is useful because it provides compactibility at relatively low use levels. A manufacturer may evaluate silicified microcrystalline cellulose or a co-processed filler-disintegrant system to improve flow and tensile strength.

The development target should be a robust tablet that can withstand coating, packaging, transport, and high-volume bottling without excessive edge chipping or abrasion.

Disintegration and dissolution

Sodium starch glycolate is a conventional choice, but its performance depends on grade, level, particle size, and lubricant exposure. Excessive magnesium stearate blending can reduce wetting and slow dissolution. A formulation team can assess crospovidone or low-substituted hydroxypropyl cellulose as alternatives, subject to comparative dissolution and stability data.

The relevant commercial objective is not a novel release profile. It is rapid, reproducible immediate release across manufacturing sites and excipient suppliers.

Moisture and chemical stability

Zidovudine, lamivudine, and abacavir have different physical and chemical properties. The formulation should control:

• Water activity during granulation and coating.
• Exposure to high humidity during storage.
• Lubricant distribution.
• Electrostatic segregation.
• Interaction between active ingredients and alkaline or acidic excipients.
• Degradation products under accelerated conditions.

A low-moisture process, controlled coating suspension, and high-barrier packaging can reduce stability risk. The final packaging decision may be more commercially important than a marginal excipient change.

Film coating

The film coat supports identification, swallowability, moisture protection, and mechanical durability. A conventional hypromellose-based coating is sufficient for most markets. Manufacturers may reduce titanium dioxide or replace it where regional regulatory or customer requirements favor titanium-dioxide-free formulations.

Color matching is commercially relevant because a changed tablet appearance can create substitution concerns in pharmacies and public tenders. Any change should preserve product identification and comply with the applicable labeling and post-approval change pathway.

What formulations are protected by patents?

The core formulation is unlikely to support meaningful current exclusivity. Trizivir’s foundational protection is historic, and the active ingredients have long been generic.

Active ingredient or product	Historic protection profile	Current commercial implication
Zidovudine	Early compound and use patents expired years ago	No meaningful compound patent barrier
Lamivudine	Historic compound and antiviral-use patents expired	Generic active ingredient widely available
Abacavir	Historic compound and use patents expired	Generic active ingredient available
Trizivir combination	Product-specific and formulation-related protection was time-limited	Any remaining value depends on regulatory status, supply, and market access

The U.S. Orange Book remains the principal source for current listed patents and exclusivity. A manufacturer evaluating an ANDA should verify the current product listing, discontinued-product status, patent-history entries, and any listed patents before filing.[3] Historic patents associated with the three active ingredients do not create a current long-term barrier to ordinary immediate-release generic tablets.

When did abacavir, lamivudine and zidovudine lose exclusivity?

The combination’s commercial exclusivity has effectively expired. Trizivir was approved in 2000, and the original compound patents covering zidovudine, lamivudine, and abacavir were not capable of sustaining exclusivity into the current market period.[1,4-6]

FDA regulatory exclusivity for a small-molecule product is separate from patent protection. Trizivir’s five-year new chemical entity exclusivity was not available for the combination in the same manner as a first approval of a new active ingredient because the product combined previously known active substances. Any pediatric extension or other regulatory exclusivity would also have expired.

The practical result is a mature generic opportunity rather than an innovator-protected product.

What is the Orange Book and Paragraph IV status?

Trizivir’s commercial lifecycle does not present the same Paragraph IV value as a recently approved branded medicine. A generic applicant can pursue an ANDA based on pharmaceutical equivalence and bioequivalence, subject to the current FDA reference-product and patent-listing record.

A Paragraph IV certification is relevant only to an unexpired listed patent. For this product, the principal legal risk is more likely to involve:

• Product-specific patent-listing interpretation.
• Reference-product availability.
• Bioequivalence against the designated reference product.
• Labeling differences.
• Discontinuation or withdrawn-status issues.
• State substitution and procurement requirements.

The combination is a small-molecule tablet, so biosimilar litigation does not apply. A manufacturer should treat the legal exposure as an ANDA and product-liability issue, not as a biologic interchangeability issue.

Which companies are challenging or competing with the product?

Competition comes from both generic versions of the three-drug tablet and newer branded or generic antiretroviral combinations.

Competitor category	Representative products	Competitive effect
Generic fixed-dose combination	Abacavir/lamivudine/zidovudine tablets	Direct price competition
Dual-NRTI backbone	Abacavir/lamivudine	Fewer tablets and less zidovudine exposure
Integrase-based single-tablet regimens	Dolutegravir/abacavir/lamivudine; bictegravir/tenofovir alafenamide/emtricitabine	Major adherence and guideline advantage
Protease inhibitor regimens	Selected boosted or unboosted combinations	Alternative treatment for specific resistance or clinical circumstances
Public-sector combination programs	Regionally registered generic products	Tender-driven price pressure

The closest branded comparator is Triumeq, which contains abacavir, lamivudine, and dolutegravir. Replacing zidovudine with dolutegravir changes the treatment class and generally improves the product’s position in contemporary treatment algorithms.[2]

What generic entry risks exist?

A generic entrant faces moderate technical risk and low-to-moderate commercial risk.

Technical risks

• High active load and large tablet size.
• Blend segregation caused by different particle sizes and densities.
• Inconsistent powder flow.
• Compression capping or sticking.
• Dissolution variability after lubricant changes.
• Moisture-related degradation.
• Color and coating nonuniformity.
• Analytical interference among multiple active ingredients.

Regulatory risks

FDA approval requires demonstration of pharmaceutical equivalence and bioequivalence, together with adequate chemistry, manufacturing, and controls documentation. Excipient substitutions are generally feasible when the formulation remains within applicable regulatory limits and the finished product meets quality and performance requirements.[7]

A manufacturer should expect scrutiny of assay, content uniformity, degradation products, dissolution, microbial quality, cleaning validation, and container-closure performance.

Commercial risks

The market may be too small to support numerous suppliers. Margin compression can occur rapidly after several ANDA approvals. Public tenders may favor the lowest landed cost, while private-sector demand may be limited by physician preference for newer regimens.

How strong is the patent estate?

The current patent estate is weak for a conventional immediate-release generic tablet. The important barriers are operational rather than exclusionary:

• Regulatory approval and site qualification.
• Reliable supply of all three active pharmaceutical ingredients.
• Consistent release testing.
• Procurement registration in multiple countries.
• Pharmacovigilance and labeling compliance.
• Tender access and local distributor relationships.

The combination does not present a meaningful biosimilar barrier, device barrier, or complex-delivery patent barrier. A new formulation patent would need to claim a real technical improvement, such as demonstrable stability, manufacturability, or patient-use benefit. A simple substitution of one standard excipient for another would face a weak inventive-step position.

What licensing deals and manufacturing opportunities exist?

The strongest opportunities are commercial and territorial rather than patent licensing opportunities.

Potential strategies include:

1. Licensing an established generic dossier into countries without local manufacturing capacity.
2. Contract manufacturing for government procurement.
3. Regional technology transfer using locally available excipients.
4. Dual sourcing of microcrystalline cellulose, disintegrant, coating polymer, and lubricant.
5. Packaging optimization for hot and humid climates.
6. Private-label supply for institutional buyers.
7. Portfolio bundling with abacavir/lamivudine and other antiretroviral products.

Licensing economics will depend on registration status, market size, tender eligibility, and supply reliability. A formulation patent license is unlikely to be necessary for an ordinary immediate-release product because the relevant active-ingredient and combination protections are mature.

What manufacturing and geographic barriers matter?

Geographic opportunity is greatest where HIV procurement remains dependent on generic solid-dose products and where treatment guidelines or formularies retain zidovudine-containing regimens.

Key regional considerations include:

• WHO prequalification or equivalent quality requirements for donor-funded procurement.
• National registration and local bioequivalence rules.
• Climatic-zone stability testing.
• Packaging suitable for humidity and temperature excursions.
• Local content or domestic manufacturing requirements.
• Serialization, pharmacovigilance, and language-specific labeling.
• Tender cycles and buffer-stock obligations.

High-barrier markets are those requiring extensive local clinical or bioequivalence data, domestic production, or stringent supplier audits. Low-cost production alone does not guarantee access to public tenders.

What is the revenue exposure?

Trizivir is unlikely to represent material revenue exposure for a major multinational pharmaceutical company compared with newer antiretroviral franchises. Revenue opportunity is more credible for generic manufacturers, contract manufacturers, and regional distributors.

Business model	Revenue outlook	Main driver
Branded innovator	Low	Therapeutic substitution and legacy demand
Large generic manufacturer	Low to moderate	Scale, tender access, and portfolio breadth
Regional manufacturer	Moderate in selected markets	Local registration and procurement relationships
Contract manufacturer	Moderate	Stable institutional volumes
Excipient supplier	Incremental	Multi-source qualification and product substitution
Specialty reformulator	Low unless a clinical advantage is established	Limited willingness to pay

Key Takeaways

• Abacavir/lamivudine/zidovudine is a mature immediate-release fixed-dose combination.
• Trizivir’s original exclusivity period has expired, and the active ingredients are broadly generic.
• The most practical excipient platform uses microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, magnesium stearate, and a hypromellose film coat.
• Excipient innovation should target tablet strength, dissolution consistency, moisture control, coating durability, and supplier resilience.
• The product has no biosimilar pathway and limited current patent-based protection.
• Generic commercial value depends on tenders, geography, manufacturing scale, and continued formulary use.
• The principal competitive threat is therapeutic substitution by dolutegravir- and bictegravir-based regimens.
• A new formulation patent is unlikely to be commercially durable without a measurable technical or clinical advantage.

FAQs

Can abacavir, lamivudine and zidovudine be manufactured by direct compression?

Yes. Direct compression or dry granulation can be evaluated, but the high active load and differing powder properties require careful control of particle size, blend uniformity, lubrication, and compression force.

Which excipient is most important for this combination tablet?

Microcrystalline cellulose is usually central to compactibility because the tablet contains a high proportion of active ingredients. The disintegrant and lubricant levels are also critical to dissolution and manufacturing performance.

Does the combination require a modified-release formulation?

No. The established product is an immediate-release tablet. Modified release would create additional development, bioequivalence, and clinical justification requirements without an obvious market advantage.

Is abacavir hypersensitivity an excipient issue?

No. The major hypersensitivity risk is associated with abacavir and HLA-B*57:01 status, not with the tablet excipients. FDA labeling requires clinically appropriate screening and management of abacavir hypersensitivity risk.[1]

Can titanium dioxide be removed from the film coating?

Yes, a titanium-dioxide-free coating can be developed, but the manufacturer must establish equivalent appearance, coating performance, stability, identification, and regulatory acceptability in each target market.

References

1. U.S. Food and Drug Administration. (2022). Trizivir: Abacavir sulfate, lamivudine, and zidovudine tablets prescribing information. FDA.

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent No. 4,724,232. (1988). Nucleoside derivatives and pharmaceutical compositions. United States Patent and Trademark Office.

5. U.S. Patent No. 5,047,407. (1991). 2',3'-dideoxy-3'-thiacytidine. United States Patent and Trademark Office.

6. U.S. Patent No. 5,034,394. (1991). Carbocyclic nucleoside analogues. United States Patent and Trademark Office.

7. U.S. Food and Drug Administration. (2014). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and postapproval changes. FDA.